[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6155 followers
Created: 2025-06-24 12:24:58 UTC

Zydus Lifesciences: Global Expansion & Sustainability Goals 🚀🌱 | MCap XXXXXXXX Cr

- FY25 revenue: ₹225.7B (~$2.75B) | EBITDA: $835M (30.4% margin) | R&D spend: $219M (8% of revenue)
- Indian Pharma Market: XXX% share | X in US generics by prescriptions
- Robust pipeline: Includes Saroglitazar (MASH/PBC), Desidustat (CKD anemia), Usnoflast (neurodegenerative diseases)
- Biosimilars: XX launched (including world's first biosimilar Trastuzumab Emtansine ADC) + XX in pipeline
- MedTech expansion: Proposed acquisition of Amplitude Surgical to enter global orthopaedics market
- CDMO entry: Acquired X biologics facilities in California for $75M upfront
- ESG goals: XX% GHG reduction by 2030 | Net carbon neutrality by 2035
- Leadership: Chairman Pankaj R. Patel & MD Dr. Sharvil P. Patel

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/GuNWG-yagAIoeWw.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1937487109251621376/c:line.svg)

**Related Topics**
[$219m](/topic/$219m)
[$835m](/topic/$835m)
[$275b](/topic/$275b)
[mcap](/topic/mcap)
[sustainability](/topic/sustainability)
[$zyduslifebo](/topic/$zyduslifebo)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1937487109251621376)